Business

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 and Gecacitinib Hydrochloride Tablets with Chemotherapy Regimen

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 and Gecacitinib Hydrochloride Tablets with Chemotherapy Regimen

articleSuzhou Zelgen Biopharmaceuticals Co. Ltd. Class AAugust 20, 20254/news/announcement-on-voluntary-disclosure-of-obtaining-notice-of-approval-for-drug-clinical-trials-of-combination-of-injectable-zg005-and-gecacitinib-hydrochloride-tablets-with-chemotherapy-regimen
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 and Gecacitinib Hydrochloride Tablets with Chemotherapy Regimen

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 and Gecacitinib Hydrochloride Tablets with Chemotherapy RegimenThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A